DIVAN: Digital Voice Analysis as a Measure of Frailty and Distress

Sponsor
University Hospital, Basel, Switzerland (Other)
Overall Status
Recruiting
CT.gov ID
NCT05783401
Collaborator
(none)
100
2
23.1
50
2.2

Study Details

Study Description

Brief Summary

This study evaluates if it is possible to identify quantitative parameters from audio signals to describe the changes in patient's state in relation to frailty and distress.

Condition or Disease Intervention/Treatment Phase
  • Other: Data acquisition: Speech acquisition
  • Diagnostic Test: Data acquisition: G8 Screening tool
  • Diagnostic Test: Data acquisition: Distress Thermometer

Detailed Description

Frailty is a common clinical syndrome especially in older adults that carries an increased risk for poor health outcomes including falls, incident disability, hospitalization, and mortality. The early detection of frailty is of importance in many patient populations to predict treatment outcomes, identify patient needs and coordinate efficient and meaningful care. An electronic assessment of the degree of distress in patients, who are unable to report, would be important to be able to routinely and objectively identify suffering in these patients. Digital voice analysis (DVA) gathers speech samples from individuals via different kinds of recording devices (smartphone, tablet, etc.) and examines a large variety of specific acoustic parameters such as for example frequency and voice quality features. This study is to analyse the potential to evaluate distress and frailty through digital voice analysis. On the contrary to the existing studies, it is intended to record audio and clinical evaluation data from the same subject multiple times during several weeks to be able to analyse temporal changes. This will allow to not only perform inter-subject but as well intra-subject comparisons of changes in audio features with changes of the patient's wellbeing over time. To make the patient speak as freely and relaxed as possible, the patient will describe different images. Different features will be extracted from the audios and potential candidates for a larger patient study will be identified, if data quantity permits using machine learning algorithms. Therefore this study evaluates if it is feasible to gather digital voice samples for voice analyses from cancer patients alongside conventional assessments for frailty (G8 questionnaire and distress (Distress Thermometer) to conduct first, preliminary analyses for identification of potential correlates between voice features and frailty or distress and between changes over time.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Digital Voice Analysis as a Measure of Frailty and Distress. A Feasibility Study (DIVAN)
Actual Study Start Date :
Nov 29, 2022
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Cohort A: palliative care center

Patients from a palliative care center (Palliativzentrum Hildegard, Basel)

Other: Data acquisition: Speech acquisition
Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.

Diagnostic Test: Data acquisition: G8 Screening tool
The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.

Diagnostic Test: Data acquisition: Distress Thermometer
The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.

Cohort B: mid-size cancer center

Patients from a mid-size cancer center (Tumorzentrum Baselland)

Other: Data acquisition: Speech acquisition
Speech test with synchronized audio and video recording. The speaking exercises and the audio and video recording will be done using a tablet computer and an application developed in-house. Freely available images showing different scenes will be integrated and displayed on the tablet to be described by the patient. The goal is to have at least two and maximum four of them described with several sentences by each patient per session. Parameters will be extracted from the patient's audio data to estimate the changes in distress and frailty.

Diagnostic Test: Data acquisition: G8 Screening tool
The G8 screening tool consists of seven items dealing with food intake, weight loss, mobility, neuropsychological problem, body mass index, prescription drug, and self-perception of health, from the Mini-Nutritional Assessment (MNA) questionnaire and was developed specifically for elderly cancer patients. The total G-8 score lies between 0 and 17. A higher score indicates a better health status.

Diagnostic Test: Data acquisition: Distress Thermometer
The distress thermometer (DT) is a measure of psychological distress in cancer patients. The instrument is a self-reported tool using a 0-to-10 rating scale.

Outcome Measures

Primary Outcome Measures

  1. Change of mean fundamental frequency extracted from the patient's audio data [during a 16-week period for each patient]

    Change of mean fundamental frequency extracted from the patient's audio data to estimate the changes in distress and frailty.

  2. Change of first few formants (F1, F2) [during a 16-week period for each patient]

    Change of first few formants (F1, F2) extracted from the patient's audio data to estimate the changes in distress and frailty.

  3. Change of jitter (variation in F0 from cycle to cycle) [during a 16-week period for each patient]

    Change of jitter (variation in F0 from cycle to cycle) extracted from the patient's audio data to estimate the changes in distress and frailty.

  4. Change of shimmer (variation in peak-to-peak amplitude) [during a 16-week period for each patient]

    Change of shimmer (variation in peak-to-peak amplitude) extracted from the patient's audio data to estimate the changes in distress and frailty.

  5. Change of skewness [during a 16-week period for each patient]

    Change of skewness extracted from the patient's audio data to estimate the changes in distress and frailty.

  6. Change of kurtosis [during a 16-week period for each patient]

    Change of kurtosis extracted from the patient's audio data to estimate the changes in distress and frailty.

  7. Change of voice strength (volume) of the vowel [during a 16-week period for each patient]

    Change of voice strength (volume) of the vowel extracted from the patient's audio data to estimate the changes in distress and frailty.

  8. Change of duration of length of the answer [during a 16-week period for each patient]

    Change of duration of length of the answer extracted from the patient's audio data to estimate the changes in distress and frailty.

  9. Change of verbal fluency [during a 16-week period for each patient]

    Change of verbal fluency extracted from the patient's audio data to estimate the changes in distress and frailty.

  10. Change of word duration of individual words [during a 16-week period for each patient]

    Change of word duration of individual words extracted from the patient's audio data to estimate the changes in distress and frailty.

  11. Change of duration of the breaks between the words [during a 16-week period for each patient]

    Change of duration of the breaks between the words extracted from the patient's audio data to estimate the changes in distress and frailty.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Active cancer or haemato-oncological malignancy

  • Adults (≥ 18 years)

  • Ability to understand, speak and read German language fluently

  • Ability to provide written consent

  • Sufficient or corrected vision to see the images

  • Sufficient auditory comprehension for participation in the study based on the therapist's clinical opinion

  • Ability to concentrate for 20-30 minutes based on the investigator's clinical opinion

  • Signed informed consent to the study

Exclusion Criteria:
  • Aphonia, dysphonia or other obvious voice alterations of patient's voice

  • Life-expectancy shorter ≤ 14 days as judged by a physician or nurse via "surprise question"

  • Breathlessness whilst speaking

  • Cognitive impairment as judged by physician or Mini-Cog in the G8 screening tool

  • Severe physical, emotional or existential suffering because of which the enrollment and participation in the study would result in patient burden, as judged by the treating physicians and their multiprofessional team members

Contacts and Locations

Locations

Site City State Country Postal Code
1 Palliativzentrum Hildegard, Basel Basel Switzerland 4002
2 Kantonsspital Baselland, Klinik für Onkologie, Hämatologie und Immuntherapie Liestal Switzerland 4410

Sponsors and Collaborators

  • University Hospital, Basel, Switzerland

Investigators

  • Principal Investigator: Marcus Vetter, PD Dr. med., Kantonsspital Baselland, Klinik für Onkologie, Hämatologie und Immuntherapie

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT05783401
Other Study ID Numbers:
  • 2022-01461; th23Vetter
First Posted:
Mar 24, 2023
Last Update Posted:
Mar 24, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Basel, Switzerland
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 24, 2023